Market News / Story
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
GlobeNewswire ·
GlobeNewswire reports: Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study…